In the original publication [], there was a mistake in the left graph of Figure 5L as published. We inadvertently duplicated the graph for PMN-MDSCs and used it in place of the graph intended to represent M-MDSCs. As a result, both graphs in Figure 5L displayed the same PMN-MDSC data, and the actual M-MDSC data was omitted.
The corrected Figure 5L appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 5.
Changes in tumor-infiltrating immune cells by RT and BRD4 inhibition. (A,B) Representative IHC images (A) and relative expression (B) of CD68 in tumors. (C,D) Representative flow cytometry plots (C) and frequencies (D) of M1 and M2 tumor-associated macrophages (TAMs) in tumors. (E,F) Representative flow cytometry plots (E) and frequencies (F) of CD8+ T cells and CD4+ T cells in tumors. (G,H) Representative IHC images (G) and relative expression (H) of CD8 in the TME. (I,J) Representative flow cytometry plots (I) and frequencies (J) of regulatory T cells (Tregs) in tumors. (K,L) Representative flow cytometry plots (K) and frequencies (L) of monocytic and polymorphonuclear myeloid-derived suppressor cells (MDSCs) in tumors. (***) p < 0.001; (**) p < 0.01; (*) p < 0.05.
Reference
- Kim, S.; Jeon, S.H.; Han, M.G.; Kang, M.H.; Kim, I.A. BRD4 Inhibition Enhances the Antitumor Effects of Radiation Therapy in a Murine Breast Cancer Model. Int. J. Mol. Sci. 2023, 24, 13062. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).